Tag Archives: Jason Mccarthy

Capricor Therapeutics (CAPR) Gets a Hold Rating from Maxim Group

In a report released today, Jason McCarthy from Maxim Group assigned a Hold rating to Capricor Therapeutics (CAPR – Research Report). The company’s shares opened today at $0.58, close to its 52-week low of $0.31. McCarthy observed: “Capricor announced it

Moleculin Biotech (MBRX) Receives a Buy from Maxim Group

Maxim Group analyst Jason McCarthy assigned a Buy rating to Moleculin Biotech (MBRX – Research Report) today and set a price target of $3. The company’s shares opened today at $1.59. McCarthy wrote: “Moleculin announced that STAT3 inhibitor WP1066 has

Maxim Group Maintains a Buy Rating on Entera Bio Ltd (ENTX)

In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Entera Bio Ltd (ENTX – Research Report), with a price target of $12. The company’s shares opened today at $4.44. McCarthy observed: “Entera Bio announced

Maxim Group Sticks to Its Buy Rating for BioTime (BTX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on BioTime (BTX – Research Report) today and set a price target of $3. The company’s shares opened today at $1.57. McCarthy observed: “BioTime announced that its affiliate, OncoCyte (OCX –

Inovio Pharmaceuticals (INO) Gets a Buy Rating from Maxim Group

Maxim Group analyst Jason McCarthy maintained a Buy rating on Inovio Pharmaceuticals (INO – Research Report) today and set a price target of $8. The company’s shares opened today at $4.55. McCarthy commented: “Inovio announced the publication of a preclinical

Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)

Maxim Group analyst Jason McCarthy maintained a Buy rating on Moleculin Biotech (MBRX – Research Report) today and set a price target of $3. The company’s shares opened today at $1.35. McCarthy noted: “Moleculin announced that it has begun recruiting